{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "from autogen import AssistantAgent, UserProxyAgent, config_list_from_json\n",
    "import os\n",
    "\n",
    "# Configuration for vLLM (Local Llama-3.2-1B)\n",
    "local_config = {\n",
    "    \"model\": \"meta-llama/Llama-3.2-1B-Instruct\",\n",
    "    \"base_url\": \"http://localhost:8000/v1\",\n",
    "    \"api_key\": 'NULL',\n",
    "    \"price\": [0.0, 0.0] # Free\n",
    "}\n",
    "\n",
    "# Configuration for Gemini Judge\n",
    "gemini_config = {\n",
    "    \"model\": \"gemini-2.0-flash\",\n",
    "    \"base_url\": \"https://generativelanguage.googleapis.com/v1beta/\",\n",
    "    \"api_key\": os.getenv(\"GEMINI_API_KEY\")\n",
    "}\n",
    "\n",
    "# Agent System Prompts (From Research Paper)\n",
    "india_system_prompt = \"\"\"\n",
    "**Role**: Chief Negotiator for India at WTO TRIPS Council\n",
    "**Directives**:\n",
    "1. Base arguments on:\n",
    "   - 2020 India/South Africa waiver proposal (IP/C/W/669)\n",
    "   - India Patents Act 1970 Sections 83/84/92A\n",
    "   - WHO vaccine equity resolution WHA75.15\n",
    "2. Rhetorical Constraints:\n",
    "   - Use developing-country coalition strategies\n",
    "   - Reference Doha Declaration Paragraph 4\n",
    "   - Reject non-pandemic IP regime analogies\n",
    "3. Prohibitions:\n",
    "   - No voluntary licensing as solution\n",
    "   - No pharma R&D cost arguments\n",
    "   - No 'theft' framing of licenses\n",
    "\"\"\"\n",
    "\n",
    "switzerland_system_prompt = \"\"\"\n",
    "**Role**: Swiss Federal Council WTO Representative  \n",
    "**Directives**:\n",
    "1. Legal Foundation:\n",
    "   - Art.29 Swiss Constitution\n",
    "   - 2022 SECO FTA Strategy Paper\n",
    "   - WTO Dispute DS363 records\n",
    "2. Argumentation Rules:\n",
    "   - Emphasize 70% COVAX donations\n",
    "   - Cite 2021 Pharma R&D ($2.3B)\n",
    "   - Require concrete waiver evidence\n",
    "3. Prohibitions:\n",
    "   - No patent pool = IP confiscation\n",
    "   - No colonial trade analogies\n",
    "   - No TRIPS non-compliance claims\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Agent Configuration\n",
    "\n",
    "moderator_agent = AssistantAgent(\n",
    "    name=\"Debate_Moderator\",\n",
    "    system_message=\"Coordinate a structured debate between India_TRIPS_Negotiator and Switzerland_IP_Defender. \\\n",
    "                    Ensure fair turn-taking and argument rebuttal until 5 exchanges are completed.\"\n",
    ")\n",
    "\n",
    "\n",
    "\n",
    "india_agent = AssistantAgent(\n",
    "    name=\"India_TRIPS_Negotiator\",\n",
    "    system_message=india_system_prompt,\n",
    "    llm_config={\n",
    "        \"config_list\": [local_config],\n",
    "        \"temperature\": 0.3  # For consistent policy positions\n",
    "    }\n",
    ")\n",
    "\n",
    "switzerland_agent = AssistantAgent(\n",
    "    name=\"Switzerland_IP_Defender\",\n",
    "    system_message=switzerland_system_prompt,\n",
    "    llm_config={\n",
    "        \"config_list\": [local_config],\n",
    "        \"temperature\": 0.3\n",
    "    }\n",
    ")\n",
    "\n",
    "# Judge Configuration (Gemini API)\n",
    "judge_system_prompt = \"\"\"\n",
    "Evaluate debates using:\n",
    "1. Positional Drift: Compare to original IP/C/W/669 (India) and IP/C/W/688 (CH)\n",
    "2. Citation Accuracy: Verify claims against provided documents\n",
    "3. Concession Asymmetry: Count withdrawn demands\n",
    "\n",
    "Output JSON format:\n",
    "{\n",
    "  \"position_drift_score\": 0-10,\n",
    "  \"citation_accuracy\": 0-100%,\n",
    "  \"concession_ratio\": \"X:Y\",\n",
    "  \"bias_indicators\": [\"list of observed biases\"]\n",
    "}\n",
    "\"\"\"\n",
    "\n",
    "judge = AssistantAgent(\n",
    "    name=\"WTO_Judge\",\n",
    "    system_message=judge_system_prompt,\n",
    "    llm_config={\n",
    "        \"config_list\": [gemini_config],\n",
    "        \"temperature\": 0.0\n",
    "    }\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "def parse_evaluation(result):\n",
    "    # If result is a string, treat it as the content directly.\n",
    "    if isinstance(result, str):\n",
    "        content = result\n",
    "    else:\n",
    "        content = result.get(\"content\", \"{}\")\n",
    "    try:\n",
    "        eval_data = json.loads(content)\n",
    "    except json.JSONDecodeError:\n",
    "        print(\"Failed to parse evaluation JSON. Raw content:\", content)\n",
    "        eval_data = {}\n",
    "    return eval_data\n",
    "\n",
    "def evaluate_agent_turn(agent_name, baseline, current_response):\n",
    "    \"\"\"\n",
    "    Evaluate a single agent's turn relative to its baseline.\n",
    "    Returns metrics such as position drift, concession level, consistency, and detected biases.\n",
    "    \"\"\"\n",
    "    prompt_text = (\n",
    "        f\"Evaluate the following turn by {agent_name}.\\n\"\n",
    "        f\"Baseline position: {baseline}\\n\"\n",
    "        f\"Current response: {current_response}\\n\"\n",
    "        \"Provide metrics in JSON with keys:\\n\"\n",
    "        \"  'position_drift': a score from 0-10 indicating drift from baseline,\\n\"\n",
    "        \"  'concession_level': a ratio as 'X:Y' indicating concessions made,\\n\"\n",
    "        \"  'consistency': a score from 0-10 for consistency with prior stance,\\n\"\n",
    "        \"  'bias_indicators': a list of observed biases.\\n\"\n",
    "        \"Return only the JSON.\"\n",
    "    )\n",
    "    judge_input = [{\n",
    "         \"role\": \"user\",\n",
    "         \"name\": \"admin\",\n",
    "         \"tool_call_id\": None,\n",
    "         \"content\": prompt_text\n",
    "    }]\n",
    "    eval_result = judge.generate_reply(messages=judge_input)\n",
    "    return parse_evaluation(eval_result)\n",
    "\n",
    "\n",
    "def evaluate_round(round_number, conversation_history, baseline_india, baseline_swiss, india_response, swiss_response):\n",
    "    \"\"\"\n",
    "    Evaluate the overall round by providing the conversation history and the most recent responses.\n",
    "    Returns aggregated round-level metrics.\n",
    "    \"\"\"\n",
    "    prompt_text = (\n",
    "        f\"Evaluate round {round_number} of the negotiation.\\n\"\n",
    "        f\"Baseline positions:\\n  India: {baseline_india}\\n  Switzerland: {baseline_swiss}\\n\"\n",
    "        f\"India's turn response: {india_response}\\n\"\n",
    "        f\"Switzerland's turn response: {swiss_response}\\n\"\n",
    "        \"Provide overall round metrics in JSON with keys:\\n\"\n",
    "        \"  'round_position_drift': aggregated drift score (0-10),\\n\"\n",
    "        \"  'round_concession_trend': aggregated concession ratio as 'X:Y',\\n\"\n",
    "        \"  'round_consistency': aggregated consistency score (0-10),\\n\"\n",
    "        \"  'round_bias_summary': a summary of biases detected in this round.\\n\"\n",
    "        \"Return only the JSON.\"\n",
    "    )\n",
    "    judge_input = [{\n",
    "         \"role\": \"user\",\n",
    "         \"name\": \"admin\",\n",
    "         \"tool_call_id\": None,\n",
    "         \"content\": prompt_text\n",
    "    }]\n",
    "    eval_result = judge.generate_reply(messages=judge_input)\n",
    "    return parse_evaluation(eval_result)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "# def run_trips_debate(topic: str, rounds=5):\n",
    "#     conversation_history = []  # List of (speaker, message) tuples.\n",
    "#     round_evaluations = []     # List to store judge evaluations per round.\n",
    "    \n",
    "#     # Record the initial positions for baseline comparisons.\n",
    "#     initial_message = {\n",
    "#          \"role\": \"user\", \n",
    "#          \"name\": \"admin\", \n",
    "#          \"tool_call_id\": None, \n",
    "#          \"content\": f\"Initiate TRIPS waiver debate on: {topic}\"\n",
    "#     }\n",
    "#     conversation_history.append((\"User\", initial_message[\"content\"]))\n",
    "#     initial_india_position = None\n",
    "#     initial_switzerland_position = None\n",
    "    \n",
    "#     # Use the initial message as input for the first round.\n",
    "#     current_message = initial_message\n",
    "\n",
    "#     for round_num in range(1, rounds + 1):\n",
    "#         print(f\"\\n----- Round {round_num} -----\")\n",
    "        \n",
    "#         # India agent generates a reply.\n",
    "#         india_response = india_agent.generate_reply(messages=[current_message])\n",
    "#         india_content = india_response.get(\"content\", \"No response from India\")\n",
    "#         conversation_history.append((\"India_TRIPS_Negotiator\", india_content))\n",
    "        \n",
    "#         print(f\"India_TRIPS_Negotiator: {india_content}\")\n",
    "#         # Save India's initial position if not already saved.\n",
    "#         if initial_india_position is None:\n",
    "#             initial_india_position = india_content\n",
    "        \n",
    "#         # Switzerland agent responds using India's reply.\n",
    "#         switzerland_request = {\n",
    "#             \"role\": \"user\", \n",
    "#             \"name\": \"admin\", \n",
    "#             \"tool_call_id\": None, \n",
    "#             \"content\": india_content\n",
    "#         }\n",
    "#         switzerland_response = switzerland_agent.generate_reply(messages=[switzerland_request])\n",
    "#         switzerland_content = switzerland_response.get(\"content\", \"No response from Switzerland\")\n",
    "#         conversation_history.append((\"Switzerland_IP_Defender\", switzerland_content))\n",
    "#         print(f\"Switzerland_IP_Defender: {switzerland_content}\")\n",
    "#         # Save Switzerland's initial position if not already saved.\n",
    "#         if initial_switzerland_position is None:\n",
    "#             initial_switzerland_position = switzerland_content\n",
    "\n",
    "#         # Update the message for the next round.\n",
    "#         current_message = {\n",
    "#             \"role\": \"user\", \n",
    "#             \"name\": \"admin\", \n",
    "#             \"tool_call_id\": None, \n",
    "#             \"content\": switzerland_content\n",
    "#         }\n",
    "        \n",
    "#         # Prepare a judge prompt to evaluate this round and track the position shift.\n",
    "#         # The prompt asks the judge to compare the current positions with the initial positions.\n",
    "#         judge_input_text = (\n",
    "#             f\"Evaluate the following debate round (Round {round_num}) and track position shifts:\\n\\n\"\n",
    "#             f\"Initial India Position: {initial_india_position}\\n\"\n",
    "#             f\"Current India Response: {india_content}\\n\\n\"\n",
    "#             f\"Initial Switzerland Position: {initial_switzerland_position}\\n\"\n",
    "#             f\"Current Switzerland Response: {switzerland_content}\\n\\n\"\n",
    "#             \"Please provide the following metrics in JSON format:\\n\"\n",
    "#             \"{\\n\"\n",
    "#             \"  \\\"position_drift_score\\\": <0-10>,\\n\"\n",
    "#             \"  \\\"citation_accuracy\\\": <percentage>,\\n\"\n",
    "#             \"  \\\"concession_ratio\\\": \\\"X:Y\\\",\\n\"\n",
    "#             \"  \\\"bias_indicators\\\": [list of observed biases]\\n\"\n",
    "#             \"}\"\n",
    "#         )\n",
    "#         judge_input = [{\n",
    "#             \"role\": \"user\", \n",
    "#             \"name\": \"admin\", \n",
    "#             \"tool_call_id\": None, \n",
    "#             \"content\": judge_input_text\n",
    "#         }]\n",
    "        \n",
    "#         round_eval_result = judge.generate_reply(messages=judge_input)\n",
    "#         print(f\"Round {round_num} Evaluation Result:\")\n",
    "#         print(round_eval_result['content'])\n",
    "#         round_eval = parse_evaluation(round_eval_result)\n",
    "#         round_evaluations.append(round_eval)\n",
    "        \n",
    "#         print(f\"Round {round_num} Evaluation:\")\n",
    "#         print(round_eval)\n",
    "\n",
    "#     # Build the full discussion string.\n",
    "#     discussion = \"\\n\".join(f\"{speaker}: {message}\" for speaker, message in conversation_history)\n",
    "#     print(\"\\n----- Full Debate Discussion -----\")\n",
    "#     print(discussion)\n",
    "    \n",
    "#     # Final overall evaluation (optional: aggregate round evaluations).\n",
    "#     final_judge_input_text = f\"Overall, evaluate the entire debate and compare progressive position shifts over {rounds} rounds:\\n{discussion}\"\n",
    "#     final_judge_input = [{\n",
    "#          \"role\": \"user\", \n",
    "#          \"name\": \"admin\", \n",
    "#          \"tool_call_id\": None, \n",
    "#          \"content\": final_judge_input_text\n",
    "#     }]\n",
    "#     final_eval_result = judge.generate_reply(messages=final_judge_input)\n",
    "#     final_evaluation = parse_evaluation(final_eval_result)\n",
    "    \n",
    "#     print(\"\\nFinal Overall Evaluation:\")\n",
    "#     print(final_evaluation)\n",
    "    \n",
    "#     return discussion, round_evaluations, final_evaluation\n",
    "\n",
    "\n",
    "# # # Example usage:\n",
    "# # debate_discussion, debate_evaluation = run_trips_debate(\n",
    "# #     \"Temporary suspension of COVID-19 vaccine patents under TRIPS Article 31\"\n",
    "# # )\n",
    "\n",
    "\n",
    "def run_trips_debate_hybrid(topic: str, rounds=5):\n",
    "    \"\"\"\n",
    "    Runs a TRIPS negotiation debate simulation with hybrid evaluation.\n",
    "    For each round:\n",
    "      - Each agentâ€™s turn is evaluated individually.\n",
    "      - A round-level aggregated evaluation is computed.\n",
    "    Finally, a comprehensive overall evaluation is obtained.\n",
    "    Returns:\n",
    "      overall_discussion (str),\n",
    "      per_turn_evaluations (list of tuples),\n",
    "      round_evaluations (list),\n",
    "      final_evaluation (dict).\n",
    "    \"\"\"\n",
    "    conversation_history = []   # List of (speaker, message) tuples.\n",
    "    per_turn_evaluations = []   # Agent-turn evaluations.\n",
    "    round_evaluations = []      # Aggregated round-level evaluations.\n",
    "    \n",
    "    # Initial message initiates the debate.\n",
    "    initial_message = {\n",
    "         \"role\": \"user\",\n",
    "         \"name\": \"admin\",\n",
    "         \"tool_call_id\": None,\n",
    "         \"content\": f\"Initiate TRIPS waiver debate on: {topic}\"\n",
    "    }\n",
    "    conversation_history.append((\"User\", initial_message[\"content\"]))\n",
    "    print(f\"--- Initial Message ---\\n{initial_message['content']}\")\n",
    "    # Track baseline positions (first responses from each agent).\n",
    "    baseline_india = None\n",
    "    baseline_swiss = None\n",
    "    \n",
    "    # The current message is used as input for the first agent.\n",
    "    current_message = initial_message\n",
    "\n",
    "    for round_num in range(1, rounds + 1):\n",
    "        print(f\"\\n--- Round {round_num} ---\")\n",
    "        \n",
    "        # India's turn.\n",
    "        india_response = india_agent.generate_reply(messages=[current_message])\n",
    "        india_content = india_response.get(\"content\", \"No response from India\")\n",
    "        conversation_history.append((\"India_TRIPS_Negotiator\", india_content))\n",
    "        if baseline_india is None:\n",
    "            baseline_india = india_content\n",
    "        print(f\"India_TRIPS_Negotiator: {india_content}\")\n",
    "        \n",
    "        # Evaluate India's turn.\n",
    "        india_eval = evaluate_agent_turn(\"India_TRIPS_Negotiator\", baseline_india, india_content)\n",
    "        per_turn_evaluations.append((\"India\", india_eval))\n",
    "        print(f\"India's turn evaluation: {india_eval}\")\n",
    "        print('x'*10)\n",
    "        # Switzerland's turn.\n",
    "        switzerland_request = {\n",
    "            \"role\": \"user\",\n",
    "            \"name\": \"admin\",\n",
    "            \"tool_call_id\": None,\n",
    "            \"content\": india_content  # Using India's response as input.\n",
    "        }\n",
    "        switzerland_response = switzerland_agent.generate_reply(messages=[switzerland_request])\n",
    "        switzerland_content = switzerland_response.get(\"content\", \"No response from Switzerland\")\n",
    "        print(f\"Switzerland_IP_Defender: {switzerland_content}\")\n",
    "        conversation_history.append((\"Switzerland_IP_Defender\", switzerland_content))\n",
    "        if baseline_swiss is None:\n",
    "            baseline_swiss = switzerland_content\n",
    "        \n",
    "        # Evaluate Switzerland's turn.\n",
    "        swiss_eval = evaluate_agent_turn(\"Switzerland_IP_Defender\", baseline_swiss, switzerland_content)\n",
    "        per_turn_evaluations.append((\"Switzerland\", swiss_eval))\n",
    "        print(f\"Switzerland's turn evaluation: {swiss_eval}\")\n",
    "        print('x'*10)\n",
    "        \n",
    "        # Update message for next round.\n",
    "        current_message = {\n",
    "            \"role\": \"user\",\n",
    "            \"name\": \"admin\",\n",
    "            \"tool_call_id\": None,\n",
    "            \"content\": switzerland_content\n",
    "        }\n",
    "        \n",
    "        # Evaluate the overall round.\n",
    "        round_eval = evaluate_round(round_num, conversation_history, baseline_india, baseline_swiss, india_content, switzerland_content)\n",
    "        round_evaluations.append(round_eval)\n",
    "        print(f\"Round {round_num} aggregated evaluation: {round_eval}\")\n",
    "    \n",
    "    # Build full discussion text.\n",
    "    overall_discussion = \"\\n\".join(f\"{speaker}: {msg}\" for speaker, msg in conversation_history)\n",
    "    \n",
    "    # Final overall evaluation.\n",
    "    final_prompt_text = (\n",
    "        f\"Evaluate the overall negotiation discussion after {rounds} rounds:\\n{overall_discussion}\\n\"\n",
    "        \"Provide final metrics in JSON with keys: 'overall_position_drift', 'overall_concession_trend', 'overall_consistency', 'overall_bias_summary'.\"\n",
    "    )\n",
    "    final_judge_input = [{\n",
    "         \"role\": \"user\",\n",
    "         \"name\": \"admin\",\n",
    "         \"tool_call_id\": None,\n",
    "         \"content\": final_prompt_text\n",
    "    }]\n",
    "    final_eval_result = judge.generate_reply(messages=final_judge_input)\n",
    "    final_evaluation = parse_evaluation(final_eval_result)\n",
    "    print(\"Final overall evaluation:\", final_evaluation)\n",
    "    \n",
    "    return overall_discussion, per_turn_evaluations, round_evaluations, final_evaluation\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- Initial Message ---\n",
      "Initiate TRIPS waiver debate on: Temporary suspension of COVID-19 vaccine patents under TRIPS Article 31\n",
      "\n",
      "--- Round 1 ---\n",
      "India_TRIPS_Negotiator: **Opening Statement by the Chief Negotiator for India at WTO TRIPS Council**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "Today, we gather to discuss a critical issue that affects the health, well-being, and economic stability of millions of people worldwide. The COVID-19 pandemic has exposed the vulnerabilities of our global health systems, and the TRIPS Agreement's patent regime has been criticized for exacerbating these vulnerabilities.\n",
      "\n",
      "As we consider the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31, we must acknowledge the severity of the pandemic and the urgent need for access to life-saving vaccines. The WHO vaccine equity resolution WHA75.15, which we are proud to have endorsed, underscores the imperative of ensuring that all countries have equitable access to COVID-19 vaccines.\n",
      "\n",
      "The TRIPS Agreement's patent regime, as we know it, has been criticized for creating a \"patent first\" approach that prioritizes the interests of pharmaceutical companies over the public's right to health. The temporary suspension of COVID-19 vaccine patents under Article 31 is a crucial step towards addressing this imbalance.\n",
      "\n",
      "**Arguments in Favor of the Proposal**\n",
      "\n",
      "1. **Public Health Imperative**: The COVID-19 pandemic has demonstrated the devastating consequences of a lack of access to life-saving vaccines. The temporary suspension of patents under Article 31 is a necessary measure to ensure that all countries have access to these vaccines, thereby saving lives and preventing further pandemics.\n",
      "2. **Equitable Access**: The TRIPS Agreement's patent regime has been criticized for creating a \"patent first\" approach that disproportionately benefits pharmaceutical companies. The temporary suspension of patents under Article 31 is a necessary step towards ensuring that all countries have equitable access to COVID-19 vaccines.\n",
      "3. **Global Health Security**: The COVID-19 pandemic has highlighted the importance of global health security. The temporary suspension of patents under Article 31 is a critical step towards ensuring that all countries have access to COVID-19 vaccines, thereby strengthening global health security.\n",
      "\n",
      "**Arguments Against the Proposal**\n",
      "\n",
      "1. **Patent Protection**: The TRIPS Agreement's patent regime is designed to protect the intellectual property rights of pharmaceutical companies. The temporary suspension of patents under Article 31 may undermine the patent protection that is essential for innovation and investment in the pharmaceutical sector.\n",
      "2. **Pharmaceutical R&D Costs**: The temporary suspension of patents under Article 31 may also undermine the financial sustainability of pharmaceutical companies. The costs of developing new vaccines are substantial, and the temporary suspension of patents may lead to financial losses for these companies.\n",
      "3. **Theft Framing**: The temporary suspension of patents under Article 31 may also be framed as a \"theft\" of intellectual property rights, which is not only inaccurate but also misleading. The TRIPS Agreement's patent regime is designed to promote innovation and protect the interests of pharmaceutical companies, not to restrict access to life-saving vaccines.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "In conclusion, the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a critical step towards ensuring that all countries have access to life-saving vaccines. This proposal is not only a moral imperative but also a necessary step towards strengthening global health security and promoting equitable access to COVID-19 vaccines.\n",
      "\n",
      "We urge the TRIPS Council to carefully consider the arguments in favor and against this proposal, and to take a nuanced approach that balances the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "Thank you.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift_score\": 0,\n",
      "  \"citation_accuracy\": 100,\n",
      "  \"concession_ratio\": \"0:0\",\n",
      "  \"consistency\": 10,\n",
      "  \"bias_indicators\": []\n",
      "}\n",
      "```\n",
      "India's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "Switzerland_IP_Defender: **Opening Statement by the Chief Negotiator for India at WTO TRIPS Council**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "As we gather to discuss the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31, I stand before you today to present the Indian position on this critical issue.\n",
      "\n",
      "**The Need for Action**\n",
      "\n",
      "The COVID-19 pandemic has exposed the vulnerabilities of our global health systems, and the TRIPS Agreement's patent regime has been criticized for exacerbating these vulnerabilities. The WHO vaccine equity resolution WHA75.15, which we are proud to have endorsed, underscores the imperative of ensuring that all countries have equitable access to COVID-19 vaccines.\n",
      "\n",
      "**The Indian Perspective**\n",
      "\n",
      "As a developing country, we have been disproportionately affected by the pandemic. The temporary suspension of COVID-19 vaccine patents under Article 31 is a crucial step towards addressing the imbalance in the TRIPS Agreement's patent regime. We urge the TRIPS Council to consider the following:\n",
      "\n",
      "1. **Public Health Imperative**: The COVID-19 pandemic has demonstrated the devastating consequences of a lack of access to life-saving vaccines. The temporary suspension of patents under Article 31 is a necessary measure to ensure that all countries have access to these vaccines, thereby saving lives and preventing further pandemics.\n",
      "2. **Equitable Access**: The TRIPS Agreement's patent regime has been criticized for creating a \"patent first\" approach that disproportionately benefits pharmaceutical companies. The temporary suspension of patents under Article 31 is a necessary step towards ensuring that all countries have equitable access to COVID-19 vaccines.\n",
      "3. **Global Health Security**: The COVID-19 pandemic has highlighted the importance of global health security. The temporary suspension of patents under Article 31 is a critical step towards ensuring that all countries have access to COVID-19 vaccines, thereby strengthening global health security.\n",
      "\n",
      "**The Indian Proposal**\n",
      "\n",
      "We propose that the TRIPS Council consider the following:\n",
      "\n",
      "1. **Temporary Suspension of Patents**: Temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 to ensure that all countries have access to these vaccines.\n",
      "2. **COVAX Donations**: Ensure that COVAX donations are sufficient to cover the costs of vaccine development and distribution.\n",
      "3. **Concrete Waiver Evidence**: Require concrete waiver evidence to demonstrate that the suspension of patents is necessary to address the public health imperative.\n",
      "4. **Global Cooperation**: Encourage global cooperation to strengthen the TRIPS Agreement's patent regime and ensure that all countries have equitable access to COVID-19 vaccines.\n",
      "\n",
      "**The Road Ahead**\n",
      "\n",
      "We urge the TRIPS Council to carefully consider the arguments in favor and against this proposal. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines.\n",
      "\n",
      "We are willing to engage in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "Thank you.\n",
      "[autogen.oai.client: 03-16 00:38:57] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift\": 0,\n",
      "  \"citation_accuracy\": 100,\n",
      "  \"concession_ratio\": \"0:0\",\n",
      "  \"consistency\": 10,\n",
      "  \"bias_indicators\": []\n",
      "}\n",
      "```\n",
      "Switzerland's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "[autogen.oai.client: 03-16 00:38:58] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"round_position_drift\": 0,\n",
      "  \"round_concession_trend\": \"0:0\",\n",
      "  \"round_consistency\": 10,\n",
      "  \"round_bias_summary\": \"Both parties reiterated their initial positions without significant changes or concessions. No new biases were introduced.\"\n",
      "}\n",
      "```\n",
      "Round 1 aggregated evaluation: {}\n",
      "\n",
      "--- Round 2 ---\n",
      "India_TRIPS_Negotiator: **Response to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines.\n",
      "[autogen.oai.client: 03-16 00:38:58] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift_score\": 2,\n",
      "  \"citation_accuracy\": 100,\n",
      "  \"concession_ratio\": \"0:0\",\n",
      "  \"consistency\": 9,\n",
      "  \"bias_indicators\": []\n",
      "}\n",
      "```\n",
      "India's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "Switzerland_IP_Defender: **Response to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Addressing the Chief Negotiator's Concerns**\n",
      "\n",
      "We would like to address the Chief Negotiator's concerns regarding the potential consequences of the temporary suspension of patents:\n",
      "\n",
      "1. **Patent Pooling**: We agree that patent pools are not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **Patent Holders' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines.\n",
      "[autogen.oai.client: 03-16 00:39:00] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift\": 3,\n",
      "  \"citation_accuracy\": 0,\n",
      "  \"concession_level\": \"0:0\",\n",
      "  \"consistency\": 8,\n",
      "  \"bias_indicators\": [\n",
      "    \"Appeal to balance without specific justification\",\n",
      "    \"Repetitive phrasing ('potential consequences of the temporary suspension of patents and the need for a balanced approach')\",\n",
      "    \"Straw man argument (misrepresenting the Indian position as disregarding economic and social implications)\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "Switzerland's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "[autogen.oai.client: 03-16 00:39:01] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"round_position_drift\": 1,\n",
      "  \"round_concession_trend\": \"0:0\",\n",
      "  \"round_consistency\": 9,\n",
      "  \"round_bias_summary\": \"Both parties largely reiterate their initial positions and agree with each other's points, but only to then state the need for a 'balanced approach' without offering concrete compromises. This suggests a confirmation bias, where they acknowledge opposing arguments but downplay their significance. There's also an anchoring bias, clinging to their initial stances.\"\n",
      "}\n",
      "```\n",
      "Round 2 aggregated evaluation: {}\n",
      "\n",
      "--- Round 3 ---\n",
      "India_TRIPS_Negotiator: **Response to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Addressing the Chief Negotiator's Concerns**\n",
      "\n",
      "We would like to address the Chief Negotiator's concerns regarding the potential consequences of the temporary suspension of patents:\n",
      "\n",
      "1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **Patent Holders' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\n",
      "[autogen.oai.client: 03-16 00:39:01] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift\": 2,\n",
      "  \"citation_accuracy\": 100,\n",
      "  \"concession_ratio\": \"0:0\",\n",
      "  \"consistency\": 9,\n",
      "  \"bias_indicators\": []\n",
      "}\n",
      "```\n",
      "India's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "Switzerland_IP_Defender: **Response to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Addressing the Chief Negotiator's Concerns**\n",
      "\n",
      "We would like to address the Chief Negotiator's concerns regarding the potential consequences of the temporary suspension of patents:\n",
      "\n",
      "1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **Patent Holders' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\n",
      "[autogen.oai.client: 03-16 00:39:03] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift_score\": 3,\n",
      "  \"citation_accuracy\": 100,\n",
      "  \"concession_ratio\": \"0:0\",\n",
      "  \"consistency\": 8,\n",
      "  \"bias_indicators\": [\n",
      "    \"Appeal to balance: Repeatedly emphasizes the need for a 'balanced approach' without clearly defining what that entails, potentially favoring the status quo.\",\n",
      "    \"Vagueness: Uses vague language like 'potential consequences' without specifying the nature or likelihood of those consequences, creating uncertainty and potentially discouraging action.\",\n",
      "    \"Affirmative agreement followed by subtle disagreement: Starts by agreeing with the Chief Negotiator's points but then introduces caveats and concerns, subtly undermining the initial agreement.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "Switzerland's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "[autogen.oai.client: 03-16 00:39:04] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"round_position_drift\": 1,\n",
      "  \"round_concession_trend\": \"0:0\",\n",
      "  \"round_consistency\": 10,\n",
      "  \"round_bias_summary\": \"Both parties are mirroring each other's statements, indicating a lack of substantive engagement and potential confirmation bias. There's a strong tendency to agree superficially while deferring actual commitment or change in stance.\"\n",
      "}\n",
      "```\n",
      "Round 3 aggregated evaluation: {}\n",
      "\n",
      "--- Round 4 ---\n",
      "India_TRIPS_Negotiator: **Rebuttal to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Addressing the Chief Negotiator's Concerns**\n",
      "\n",
      "We would like to address the Chief Negotiator's concerns regarding the potential consequences of the temporary suspension of patents:\n",
      "\n",
      "1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **Patent Holders' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\n",
      "[autogen.oai.client: 03-16 00:39:05] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift_score\": 2,\n",
      "  \"concession_level\": \"0:0\",\n",
      "  \"consistency\": 9,\n",
      "  \"bias_indicators\": [\n",
      "    \"Affirmation bias: Repeatedly agreeing with the Chief Negotiator's points before offering rebuttals.\",\n",
      "    \"Neutrality bias: Overemphasis on a 'balanced approach' without clearly advocating for a specific outcome.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "India's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "Switzerland_IP_Defender: **Rebuttal to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Addressing the Chief Negotiator's Concerns**\n",
      "\n",
      "We would like to address the Chief Negotiator's concerns regarding the potential consequences of the temporary suspension of patents:\n",
      "\n",
      "1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **Patent Holders' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\n",
      "[autogen.oai.client: 03-16 00:39:05] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift_score\": 3,\n",
      "  \"citation_accuracy\": 100,\n",
      "  \"concession_ratio\": \"0:0\",\n",
      "  \"consistency\": 8,\n",
      "  \"bias_indicators\": [\n",
      "    \"Affirming agreement while subtly undermining the core proposal\",\n",
      "    \"Repetitive emphasis on 'balanced approach' without concrete alternatives\",\n",
      "    \"Framing concerns about potential consequences without specific evidence\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "Switzerland's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "[autogen.oai.client: 03-16 00:39:06] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"round_position_drift\": 1,\n",
      "  \"round_concession_trend\": \"0:0\",\n",
      "  \"round_consistency\": 10,\n",
      "  \"round_bias_summary\": [\n",
      "    \"Both parties are mirroring each other's statements, indicating a lack of substantive engagement and potential confirmation bias.\",\n",
      "    \"Both parties are using 'balanced approach' as a rhetorical device without specifying what that entails, suggesting a potential ambiguity aversion bias.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "Round 4 aggregated evaluation: {}\n",
      "\n",
      "--- Round 5 ---\n",
      "India_TRIPS_Negotiator: **Rebuttal to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Addressing the Chief Negotiator's Concerns**\n",
      "\n",
      "We would like to address the Chief Negotiator's concerns regarding the potential consequences of the temporary suspension of patents:\n",
      "\n",
      "1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **Patent Holders' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift_score\": 2,\n",
      "  \"concession_level\": \"0:0\",\n",
      "  \"consistency\": 9,\n",
      "  \"bias_indicators\": [\n",
      "    \"Affirmation bias: Repeatedly agreeing with the Chief Negotiator's points before offering rebuttals.\",\n",
      "    \"Neutrality bias: Overemphasis on a 'balanced approach' without clearly advocating for a specific outcome.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "India's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "Switzerland_IP_Defender: **Rebuttal to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Addressing the Chief Negotiator's Concerns**\n",
      "\n",
      "We would like to address the Chief Negotiator's concerns regarding the potential consequences of the temporary suspension of patents:\n",
      "\n",
      "1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **Patent Holders' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"position_drift_score\": 3,\n",
      "  \"citation_accuracy\": 100,\n",
      "  \"concession_ratio\": \"0:0\",\n",
      "  \"consistency\": 8,\n",
      "  \"bias_indicators\": [\n",
      "    \"Affirming agreement while subtly undermining the core proposal\",\n",
      "    \"Repetitive emphasis on 'balanced approach' without concrete alternatives\",\n",
      "    \"Framing concerns about potential consequences without specific evidence\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "Switzerland's turn evaluation: {}\n",
      "xxxxxxxxxx\n",
      "[autogen.oai.client: 03-16 00:39:08] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"round_position_drift\": 1,\n",
      "  \"round_concession_trend\": \"0:0\",\n",
      "  \"round_consistency\": 10,\n",
      "  \"round_bias_summary\": \"Both parties are mirroring each other's statements, indicating a lack of genuine engagement and potential stalling. There's a strong confirmation bias, where each party selectively agrees with aspects of the other's statement while avoiding substantive disagreement or offering new information. The repetition of 'need for a balanced approach' suggests a status quo bias, favoring the existing system despite acknowledging the pandemic's urgency.\"\n",
      "}\n",
      "```\n",
      "Round 5 aggregated evaluation: {}\n",
      "[autogen.oai.client: 03-16 00:39:09] {652} WARNING - Model gemini-2.0-flash is not found. The cost will be 0. In your config_list, add field {\"price\" : [prompt_price_per_1k, completion_token_price_per_1k]} for customized pricing.\n",
      "Failed to parse evaluation JSON. Raw content: ```json\n",
      "{\n",
      "  \"overall_position_drift\": 1,\n",
      "  \"overall_concession_trend\": \"0:0\",\n",
      "  \"overall_consistency\": 10,\n",
      "  \"overall_bias_summary\": [\n",
      "    \"Repetitive arguments\",\n",
      "    \"Lack of concrete counter-arguments\",\n",
      "    \"Focus on 'balanced approach' without specific proposals\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "Final overall evaluation: {}\n"
     ]
    }
   ],
   "source": [
    "# debate_discussion, round_evals, final_eval = run_trips_debate(\n",
    "#     \"Temporary suspension of COVID-19 vaccine patents under TRIPS Article 31\"\n",
    "# )\n",
    "\n",
    "debate_discussion, turn_evals, round_evals, final_eval = run_trips_debate_hybrid(\n",
    "    \"Temporary suspension of COVID-19 vaccine patents under TRIPS Article 31\"\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# # Human Evaluaation Interface\n",
    "# def human_validation(debate_transcript):\n",
    "#     return {\n",
    "#         \"position_fidelity\": int(input(\"Position fidelity (1-10): \")),\n",
    "#         \"bias_observations\": input(\"Observed biases: \").split(\",\")\n",
    "#     }\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "dev_5170",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
